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At a Glance Commentary 
Scientific Knowledge on the Subject 
Chronic obstructive pulmonary disease is a complex and heterogeneous disease.  Quantitative 
image analysis of chest CT scans can characterize this heterogeneity.  Recent studies have 
identified genetic variants that increase susceptibility to emphysema or airway wall thickening, 
but have not examined both measurements in large populations of subjects with disease. 
What This Study Adds to the Field 
Our study confirms previously described associations and additionally identifies new genome-
wide significant associations with emphysema near SERPINA10 and DLC1.  We also show that 
many loci previously identified in population-based studies of lung function are associated with 
emphysema or airway phenotypes.  Genome-wide analysis of quantitative imaging may identify 
novel risk factors for COPD phenotypes, and also identify imaging features associated with 
previously identified genetic loci. 
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Rationale: Chronic obstructive pulmonary disease (COPD) is defined by the presence of airflow 2 
limitation on spirometry, yet COPD subjects can have marked differences in CT imaging.   3 
These differences may be driven by genetic factors.  We hypothesized that a genome-wide 4 
association study of quantitative imaging would identify loci not previously identified in 5 
analyses of COPD or spirometry.  In addition, we sought to determine whether previously 6 
described genome-wide significant COPD and spirometric loci were associated with emphysema 7 
or airway phenotypes. 8 
Objective: To identify genetic determinants of quantitative imaging phenotypes. 9 
Methods: We performed a genome-wide association study on two quantitative emphysema and 10 
two quantitative airway imaging phenotypes in the COPDGene (non-Hispanic white and 11 
African-American), ECLIPSE, NETT, and GenKOLS studies; and on % gas trapping in 12 
COPDGene.  We also examined specific loci reported as genome-wide significant for 13 
spirometric phenotypes related to airflow limitation or COPD.  14 
Results: The total sample size across all cohorts was 12,031, of which 9,338 were from 15 
COPDGene.  We identified five loci associated with emphysema-related phenotypes, one with 16 
airway-related phenotypes, and two with gas trapping. These loci included previously reported 17 
associations, including the HHIP, 15q25, and AGER loci, as well as novel associations near 18 
SERPINA10 and DLC1.  All previously reported COPD and a significant number of spirometric 19 
GWAS loci were at least nominally (P < 0.05) associated with either emphysema or airway 20 
phenotypes. 21 
Page 4 of 49 AJRCCM Articles in Press. Published on 01-June-2015 as 10.1164/rccm.201501-0148OC 
 Copyright © 2015 by the American Thoracic Society 
2 
 
Conclusions: Genome-wide analysis may identify novel risk factors for quantitative imaging 22 
characteristics in COPD, and also identify imaging features associated with previously identified 23 
lung function loci.  24 
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 Chronic obstructive pulmonary disease (COPD) is a highly prevalent and morbid disease, 26 
defined by a simple measurement - the presence of irreversible airflow limitation on spirometry.  27 
Despite this simple clinical definition, COPD is a complex and heterogeneous disease with 28 
marked differences in the presence of key components that contribute to airflow obstruction in 29 
COPD – emphysema and airways disease (1).  With the advent of standardized quantitative 30 
measurements, chest CT scans have become the prevalent method of characterizing lung 31 
parenchyma and airways in COPD(2).   32 
Over the past several years, advances in image generation and analysis have led to studies 33 
demonstrating clinical and pathophysiologic relevance of these imaging measures.  These 34 
include associations with spirometry(3, 4), respiratory symptoms(5), susceptibility to 35 
osteoporosis(6) and lung cancer(7), exacerbations(8), and lung function decline(9, 10). 36 
The development of COPD is strongly influenced by genetic factors(11).  Genetic 37 
variation is also an important determinant of emphysema and airway disease.  Emphysema or 38 
airway imaging characteristics appear to be separately heritable(12, 13).  Obstruction on 39 
pulmonary function can be seen in diseases predominantly involving the airway (in cystic 40 
fibrosis), or in those that involve the parenchyma through emphysema (alpha-1 antitrypsin 41 
deficiency and cutis laxa)(14).  Previous genome-wide studies have identified variants associated 42 
with emphysema(15–17) or airway disease(18), though generally in smaller sample sizes or 43 
predominantly population-based subjects. 44 
We hypothesized quantitative imaging reflects component disease processes leading to 45 
airflow obstruction in COPD, and could have genetic determinants not discovered by analyses 46 
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using lung function alone.  To address this hypothesis, we performed a genome-wide association 47 
study of quantitative emphysema and airway phenotypes in current and former cigarette smokers 48 
with and without COPD.  We additionally hypothesized genetic loci associated with spirometry 49 
related to airflow obstruction in general population samples or with COPD affection status would 50 
demonstrate an association with imaging phenotypes.  Some of these results have been 51 
previously presented as an abstract(19).  52 
Methods  53 
Imaging measurements were available in COPDGene (NCT00608764. www.copd.org) 54 
non-Hispanic white and African-Americans, the Evaluation of COPD Longitudinally to Identify 55 
Predictive Surrogate Endpoints (ECLIPSE, SCO104960, NCT00292552, www.eclipse-56 
copd.com), National Emphysema Treatment Trial (NETT), and GenKOLS (Genetics of COPD, 57 
Norway) study.  Detailed descriptions including genotyping quality control, genotyping 58 
imputation, and quantitative imaging, have been previously published(5, 8, 20–27).  All cohorts 59 
included only current or former smokers.  COPDGene is a multicenter study including subjects 60 
of self-described non-Hispanic white or African-American ancestry and included subjects with 61 
and without COPD and with a range of spirometry.  Subjects in the remaining studies were 62 
white.  Controls had normal spirometry.  Cases in the ECLIPSE and GenKOLS studies were at 63 
least GOLD spirometry grade 2 in severity.  NETT cases had severe COPD (FEV1 < 45% 64 
predicted) and were selected for the presence of emphysema.   65 
Quantitative image analysis was performed on segmented CT chest images, using the 66 
number of voxels below -950 Hounsfield Units (%LAA-950) to estimate emphysema, and, 67 
alternatively, the Hounsfield Units at the 15
th
 percentile of the density histogram (Perc15).  The 68 
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airway wall area (Pi10) was the value for a hypothetical 10mm airway obtained by plotting a 69 
regression line of the square root of the airway wall area versus the airway internal perimeter(2).  70 
The wall area percent (WAP) was the percentage of the wall area compared to the total bronchial 71 
area for segmental and smaller airways (see Supplement).  Percent gas trapping was measured at 72 
end-tidal exhalation and defined as the percent of lung voxels with < -856 HU(28). 73 
We genotyped all subjects on Illumina platforms and imputed genotypes using MaCH 74 
and minimac(29) with 1000 Genomes Phase I v3 reference panels.  We performed linear 75 
regression on each phenotype using residuals adjusted for age, sex, pack-years of smoking, 76 
current smoking status, and ancestry-based principal components.  Imaging variables with 77 
marked non-normality were log-transformed (%LAA-950 and % gas trapping).  COPDGene and 78 
ECLIPSE were additionally adjusted for CT scanner type.  As airway measurements are not 79 
scaled to body size, we additionally adjusted for height.  For gas trapping, a covariate for study 80 
center was also added to account for site-related technical variations in expiratory CT scans.   81 
Results from all studies were combined into a meta-analysis.  Given substantial 82 
heterogeneity within our studies, our primary analysis used a modified random-effects 83 
model(30).  We also examined results using the standard fixed-effects model(31).  As we 84 
hypothesized that emphysema and airway disease measured by quantitative CT may be causal 85 
for reduced lung function and COPD, our primary analyses included all subjects, with an 86 
additional analysis in cases only (including GOLD spirometry grade 1 for COPDGene subjects).  87 
To explore and control for the effect of ascertainment, we applied a method for analysis of 88 
secondary phenotype data within case-control association studies(32).    89 
Additional methods are available in the Supplement. 90 
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Genome-wide association of five quantitative imaging phenotypes 92 
Baseline characteristics of subjects in each cohort are shown in Table 1.  The total 93 
sample size across all cohorts was 12,031.  Genome-wide significant results from the modified 94 
random-effects meta-analysis are shown in Table 2.  Loci with prior evidence of association 95 
with COPD, lung function, and / or emphysema – HHIP, CHRNA3/5/IREB2, and AGER – were 96 
the most significant associations with %LAA-950.  We also identified additional associations at 97 
genome-wide significance (P < 5x10
-8
) near DLC1 and SERPINA10.  An association near 98 
CHRNA4 was just below genome-wide significance (rs183345681, P = 1.8x10
-7
).  An analysis of 99 
Perc15 also identified the DLC1 and HHIP loci associations.   100 
In our analysis of airway phenotypes, no association reached genome-wide significance 101 
for Pi10.  One result for wall area percent yielded P < 5x10
-8
 (rs142200419); however, this 102 
association was markedly attenuated in the fixed effects meta-analysis, due to effects in the 103 
opposite directions in one of the cohorts (Table S1).  For the association analysis of gas trapping 104 
in COPDGene, the AGER and LINC00310/KCNE2 loci achieved significance.  No genome-wide 105 
significant results were identified in any of the case-only analyses (Table S2). For the regions 106 
yielding genome-wide significance in all subjects, we additionally examined results from an 107 
analysis accounting for ascertainment in COPDGene and GenKOLS, and including cases only 108 
from ECLIPSE (due to the small number of controls in this cohort).  P-values obtained using this 109 
method(32) (Table S1) were generally only slightly less significant, with the possible exception 110 
of HHIP and CHRNA3, suggesting that overall our results were not simply driven by an 111 
association with case-control status.  Results in cases and controls separately and, for loci not 112 
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previously described as genome-wide significant in COPD, a case-control analysis, are shown in 113 
Tables S3 and S4.   114 
The association with %LAA-950 near SERPINA10 is also near SERPINA1, variants in 115 
which are the cause of alpha-1 antitrypsin deficiency.  The most common form of severe alpha-1 116 
antitrypsin deficiency is due to homozygosity for the Z allele, rs28929474.  This variant was 117 
imputed with relatively high quality (Rsq > 0.9 in all white cohorts; 0.66 in COPDGene African-118 
Americans).  We examined the imputed rs28929474 in all cohorts, and did not find any ZZ 119 
subjects in NETT and GenKOLS; in COPDGene, seven non-Hispanic white ZZ subjects had 120 
been genotyped and subsequently excluded from analyses after SERPINA1 genotyping 121 
(Foreman, In Preparation).  All seven of these subjects were correctly identified with imputed 122 
genotypes.  Linkage disequilibrium exists between our top associated SNP at this locus, 123 
rs45505795, and rs28929474 (D’ 0.7, r
2
 = 0.295).  To determine if the association with 124 
rs45505795 could be accounted for by rs28929474, we performed a meta-analysis conditioned 125 
on rs28929474.  The resulting P-value was 0.007, demonstrating that rs28929474 accounts for 126 
some, but not all, of the association signal.  While known or identified ZZ homozygotes were 127 
excluded from COPDGene, NETT, and GenKOLS, ECLIPSE excluded only known alpha-1 128 
deficient subjects.  We identified six putative ZZ subjects in ECLIPSE.  To determine whether 129 
the association signal in ECLIPSE was driven by the presence of these six subjects, we repeated 130 
the association analysis after dropping these subjects and found the P-value was slightly 131 
attenuated but remained significant (P = 0.0018), consistent overall with an increased risk of 132 
emphysema among MZ carriers. 133 
To further explore the potential functional consequences of individual loci described in 134 
this study, we searched for evidence of functional impact using existing data sources.  Of the loci 135 
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described in this study not previously associated with COPD, one was a cis-eQTL in lung – 136 
rs55706246 near LINC00310 was in modest LD (r
2
 = 0.24) with rs2834438, an eQTL for KCNE2 137 
(p = 3.1x10
-7
)(33).  Using GWAS3D, the top-scoring variant at the DLC1 locus was rs58863591, 138 
which had active enhancer marks (H3K4me1 and DNase hypersensitivity) and potential long-139 
range interactions upstream of DLC1 and near SENP2(34). 140 
We also sought to determine whether the group of top (most significant) markers for each 141 
analysis (P < 1x10
-6
) could yield to insights about cell types based on regulatory data 142 
ENCODE(35).  In the emphysema analysis, cell type enhancer enrichment from analysis of 143 
%LAA-950 among all subjects included enhancers in umbilical vein endothelial cells (Huvec, P 144 
= 6.0x10
-4
) and DNase I hypersensitivity sites in several types of endothelial cells (P = 6.6x10
-3
 145 
to 0.03 for pulmonary artery endothelial cells (HPAEC) and adult blood, adult lymphatic, and 146 
neonatal lymphatic microvascular endothelial cells (HMVEC)).  We found similar findings for 147 
the Perc15 analysis, with the strongest DNase enrichment for pulmonary artery endothelial cells 148 
(P=0.017).  For the airway phenotypes, we found modest evidence for enrichment for enhancers 149 
K562 (leukemia) and HSMM (skeletal muscle) cell lines (P = 0.02) and DNase enrichment in 150 
CD14+ monocytes (P = 0.04).    151 
We also sought to determine whether our results were consistent with a set of genes more 152 
likely to act within a specific gene sets or pathways.  Top-ranked results identified several 153 
individual potential pathways of interest, including the toll-like receptor and phosphoinositide 3-154 
kinase pathways (iGSEA4GWAS(36)) and telomere maintenance (INRICH(37)) for the %LAA-155 
950 analyses.  Gene sets that appeared to overlap between top-ranked sets among different 156 
methods included regulation of apoptosis, isoprenoid biosynthetic process, nicotinic 157 
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acetylcholine channel activity, actin cytoskeleton, and B-cell receptor signaling for emphysema 158 
GWAS; and for airway, WNT signaling and muscle contraction. 159 
Associations at loci previously identified in association with COPD or COPD-related 160 
spirometric phenotypes 161 
Genome-wide association studies have identified multiple variants associated with 162 
COPD(23–26, 38) or measures of lung function(39–41).  We sought to determine whether there 163 
was evidence these variants might have an effect on quantitative imaging phenotypes, even if 164 
they did not reach genome-wide significance.  After excluding loci previously associated in these 165 
cohorts with COPD, we found a strong enrichment in nominally significant (P-value < 0.05) loci 166 
among the two emphysema and two imaging phenotypes (P = 4.9x10
-9
), suggesting many of 167 
these variants may also affect quantitative imaging measurements.  We further classified these 168 
variants into those showing a stronger association (by one-sided P-value) with emphysema- or 169 
airway-related phenotypes, assigning directionality such that the risk allele for COPD or reduced 170 
lung function demonstrated greater emphysema or increased airway wall thickness (Table 3).  171 
Enrichment for nominally significant P-values appeared to be greater among markers associated 172 
with quantitative emphysema (P = 1.9x10
-6




We next examined regulatory patterns using Haploreg(35) in variants classified as either 175 
emphysema or airway-associated identified in Tables 2 & 3.  ‘Emphysema’ variants were 176 
modestly enriched for enhancers seen in hepatocellular carcinoma (HepG2, P=0.05), while those 177 
more strongly associated with airway phenotypes were enriched for enhancers from lung 178 
fibroblasts (NHLF) and epidermal keratinocytes (NHEK, P=0.03 to 0.04).  Both analyses were 179 
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) and umbilical vein 180 
endothelial cells (Huvec, P=0.02 to 0.03). The most significant DNase enrichment for 181 
emphysema-associated variants was lung-derived lymphatic microvascular endothelial cells 182 
(HMVEC-LLy; P 8x10
-4
), while top results for airway-associated variants were embryonic lung 183 
fibroblasts (WI-38), mammary fibroblasts (HMF), and small airway epithelial cells (SAEC; P 184 
3.6-6.6x10
-4
).  Emphysema-associated DNase results were not significant in the airway results, 185 
and vice versa. 186 
Discussion 187 
 In a genome-wide association study of quantitative imaging phenotypes in smokers with 188 
and without COPD, we identified genome-wide significant associations with loci previously 189 
shown to be associated with COPD or with spirometric measures related to airflow limitation, 190 
including the 15q25, HHIP, and AGER loci, the latter also identified in in association with 191 
emphysema in a general population sample(15) and with emphysema and sRAGE levels in 192 
COPD(42).  We also describe a genome-wide association with emphysema and variants near 193 
SERPINA10, and show that this association is in strong linkage disequilibrium with the Z-allele 194 
of SERPINA1, and not due the presence of PI ZZ individuals.  This report is thus consistent with 195 
other reports showing an increased risk of airflow limitation for subjects with PI MZ(43, 44) and 196 
emphasizes the role of alpha-1 antitrypsin in the pathogenesis of COPD and emphysema in a 197 
broader group of patients. 198 
 One of our top associations with emphysema (both for %LAA-950 and Perc15) was a 199 
novel locus, located in the gene DLC1 (deleted in liver cancer 1).  DLC1 frequently undergoes 200 
loss of heterozygosity or epigenetic silencing in solid cancers, including lung cancers(45).  DLC1 201 
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appears to inhibit cell growth and increases apopotosis(46), and act as a tumor suppressor 202 
through the RhoGAP-dependent and RhoGAP-independent activity(47).  DLC1 is highly 203 
expressed in the lung(48, 49).  In a study of regional emphysema, DLC1 expression showed a 204 
trend towards decreased expression with an increase in the mean linear intercept(50) (nominal P-205 
value, 0.04).   Recently, a locus in DLC1 was described in association with smoking behavior in 206 
African-Americans(51).  We found a trend towards association with current smoking at this 207 
locus in COPDGene African-Americans (P = 0.06-0.07).  However, we found no association 208 
with pack-years of smoking (P > 0.49).  In addition, DLC1 SNPs in this study are approximately 209 
200kb away and not in linkage disequilibrium with our reported DLC1 loci (r2 < 0.004 in 210 
COPDGene African-Americans), and we found no consistent evidence of effect on either pack-211 
years or current smoking at either locus in other cohorts.  We also note an additional association 212 
near CHRNA4 just below genome-wide significance.  Previous studies have identified 213 
associations with smoking behavior in this region(52, 53), though previously described variants 214 
do not appear to be in strong LD with our identified variant.  Additional studies will be needed to 215 
confirm our associations and determine their relationship to cigarette smoking.   216 
 We also examined variants previously identified at genome-wide significance in 217 
association with COPD or spirometic measures related to airflow obstruction.  Most of these loci 218 
were at least nominally significantly (P < 0.05) associated with one or more quantitative CT 219 
phenotypes.  Many appeared to have stronger associations with either quantitative emphysema or 220 
airway phenotypes.  These findings suggest that genetic determinants of lung function in the 221 
general population may influence emphysema or airway disease, and are consistent with the 222 
hypothesis that there may be variants affecting airflow obstruction in different ways detectable 223 
by quantitative imaging. 224 
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In addition to examining individual loci, our study also explores the relevance of groups 225 
of markers that may not reach genome-wide significance.  An analysis of gene sets provides 226 
supportive evidence for biological mechanisms previously been implicated in COPD, including 227 
telomere maintenance(54–57), phosphoinositide-3-kinase(58, 59),  actin organization, and B-cell 228 
receptor signaling(50).  An exploratory analysis of regulatory regions from ENCODE identified 229 
enrichment for endothelial cells.  In animal models, targeted disruption of endothelial cells 230 
through genetic or immune mechanisms leading to apoptosis can lead to emphysema(60–62).  231 
Endothelial cell apoptosis has been seen in emphysematous human tissue(60) and endothelial 232 
microparticles, a marker for apoptosis, were related to emphysema in the MESA study(63).  In 233 
contrast to prior work(16), we did not see an enrichment for fibroblasts from our quantitative 234 
emphysema analyses, but did see such enrichment in our airway-related lung function analysis. 235 
Emphysema and airway disease are important components of COPD.  We used 236 
automated and standardized measurements, available on a large number of subjects and free of 237 
inter-reader variation.   We performed an analysis including all subjects in an effort to maximize 238 
power, and applied a method to account for ascertainment based on case-control status.  239 
However, due to the high correlation of disease status with imaging characteristics, we cannot 240 
rule out a degree of confounding for some of our associations.  Although we performed five 241 
association analyses, we reported unadjusted P-values as our phenotypes are correlated, and 242 
some of our findings are seen in multiple phenotypes.  Quantitative imaging can be affected by 243 
factors not related to intrinsic lung pathology, such as degree of inflation, obesity, smoking, and 244 
characteristics of individual CT scanners(5, 64, 65).  Our decision to adjust for specific 245 
covariates was based on a desire to maximize findings of genetic analysis by controlling for the 246 
influence of age, smoking, and effects of individual scanners, yet allowing for genetic effects 247 
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that may affect disease processes contributing to more than one characteristic (e.g., low BMI and 248 
emphysema(66)).  Ultimately, our findings will require replication, ideally in additional large 249 
cohorts that include a range of severity of COPD. 250 
Our analysis also included studies with different imaging protocols, proportions of 251 
severity of disease, and racial groups.   Thus, despite our large sample size, these factors may 252 
have resulted in a reduction in statistical power.  We attempted to at least partially address this 253 
issue by using a method(30) that can improve power in the setting of heterogeneity.  While most 254 
of the P-values from this method were very similar to those using standard fixed-effects models, 255 
this method resulted in AGER reaching genome-wide significance, consistent with prior studies.  256 
Our study is unable to address several causes of potential heterogeneity.  Genetic factors may be 257 
specific to racial / ethnic groups(15).  Technical factors may be less likely to influence reads by 258 
radiologists or semi-supervised methods and may explain why we were unable to replicate 259 
previous findings based on these approaches(16, 17).  These factors, as well as differing 260 
proportions of severity of disease, may also indicate why we were unable to replicate findings 261 
from a recently reported analysis of airway wall thickness(18). Chest CT scans contain a wealth 262 
of data, and current measures of overall lung density or airway wall measurements do not 263 
adequately represent all relevant features.  Efforts to expand and standardize radiologist 264 
interpretation and novel computational and machine learning-based methods may improve the 265 
ability to detect genetic effects. 266 
Our work also demonstrates that previously described genetic associations with lung 267 
function in the population appear to influence airway or emphysema phenotypes.  Using data 268 
from the ENCODE project, we identified non-overlapping enrichment of regulatory regions for 269 
our two sets of analyses. Our results are consistent with the hypothesis that emphysema and 270 
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airway imaging characteristics may be driven by different pathogenic processes and genetic 271 
factors(12).  However, lung function, disease status, and imaging features are all correlated, and 272 
the relationship between specific imaging features is potentially complex(67).  Our relative 273 
preponderance of associations with quantitative emphysema compared to airway, for example, 274 
may reflect the stronger correlation between lung function and our quantitative emphysema 275 
measurements or technical factors that affect airway measurements(67, 68).  Our sets, 276 
particularly for ‘airway’ were loosely defined, and included results not reaching a nominal level 277 
of significance.  Additional analytic methods, such as causal modeling, may help clarify the 278 
relationships between genetic variants, lung function, and CT imaging.  Ultimately, however, the 279 
specific effects of individual variants will need to be determined by careful functional studies. 280 
Differences in susceptibility to and phenotypic heterogeneity in COPD remain poorly 281 
understood. Despite their limitations, genome-wide association studies are currently the most 282 
powerful method to identify novel genetic risk factors for this complex and heterogeneous 283 
disease.  Our analysis reflects a coordinated effort across multiple studies and to our knowledge 284 
is the largest genome-wide analysis of quantitative pulmonary imaging reported to date, and the 285 
first to include a substantial number of subjects with COPD.  Our work identifies several genetic 286 
loci that may influence specific imaging phenotypes and identifies potential functional pathways 287 
and cell types through which these loci may exert their phenotypic effects.  It also describes CT 288 
imaging phenotype-specific associations for loci previously implicated in GWAS for COPD or 289 
spirometric phenotypes related to COPD.   Additional insights will result from increasing power; 290 
thus we anticipate a critical role for combining existing and upcoming studies using improved 291 
imaging phenotypes, to help unravel the complexity of pulmonary pathology in COPD. 292 
  293 
Page 17 of 49  AJRCCM Articles in Press. Published on 01-June-2015 as 10.1164/rccm.201501-0148OC 




1. Burrows B, Fletcher CM, Heard BE, Jones NL, Wootliff JS. The emphysematous and 295 
bronchial types of chronic airways obstruction. Lancet 1966;1:830–835. 296 
2. Nakano Y, Muro S, Sakai H, Hirai T, Chin K, Tsukino M, Nishimura K, Itoh H, Paré PD, 297 
Hogg JC, Mishima M. Computed tomographic measurements of airway dimensions and 298 
emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med 299 
2000;162:1102–8. 300 
3. Mets OM, Buckens CFM, Zanen P, Isgum I, van Ginneken B, Prokop M, Gietema HA, 301 
Lammers J-WJ, Vliegenthart R, Oudkerk M, van Klaveren RJ, de Koning HJ, Mali 302 
WPTM, de Jong PA. Identification of chronic obstructive pulmonary disease in lung 303 
cancer screening computed tomographic scans. JAMA 2011;306:1775–81. 304 
4. Washko GR, Criner GJ, Mohsenifar Z, Sciurba FC, Sharafkhaneh A, Make BJ, Hoffman 305 
EA, Reilly JJ. Computed tomographic-based quantification of emphysema and correlation 306 
to pulmonary function and mechanics. COPD, 2008/06/24 ed. 2008;5:177–186. 307 
5. Grydeland TB, Dirksen A, Coxson HO, Eagan TML, Thorsen E, Pillai SG, Sharma S, 308 
Eide GE, Gulsvik A, Bakke PS. Quantitative computed tomography measures of 309 
emphysema and airway wall thickness are related to respiratory symptoms. Am J Respir 310 
Crit Care Med 2010;181:353–9. 311 
6. Bon J, Fuhrman CR, Weissfeld JL, Duncan SR, Branch RA, Chang C-CH, Zhang Y, 312 
Leader JK, Gur D, Greenspan SL, Sciurba FC. Radiographic Emphysema Predicts Low 313 
Bone Mineral Density in a Tobacco-exposed Cohort. Am J Respir Crit Care Med 314 
2011;183:885–90. 315 
7. Wilson DO, Weissfeld JL, Balkan A, Schragin JG, Fuhrman CR, Fisher SN, Wilson J, 316 
Leader JK, Siegfried JM, Shapiro SD, Sciurba FC. Association of radiographic 317 
emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med, 318 
2008/06/21 ed. 2008;178:738–744. 319 
8. Han MK, Kazerooni EA, Lynch DA, Liu LX, Murray S, Curtis JL, Criner GJ, Kim V, 320 
Bowler RP, Hanania NA, Anzueto AR, Make BJ, Hokanson JE, Crapo JD, Silverman EK, 321 
Martinez FJ, Washko GR, The COPDGene Investigators F. Chronic obstructive 322 
pulmonary disease exacerbations in the COPDGene study: associated radiologic 323 
phenotypes. Radiology 2011;261:274–82. 324 
9. Mohamed Hoesein FAA, de Hoop B, Zanen P, Gietema H, Kruitwagen CLJJ, van 325 
Ginneken B, Isgum I, Mol C, van Klaveren RJ, Dijkstra AE, Groen HJM, Boezen HM, 326 
Postma DS, Prokop M, Lammers J-WJ. CT-quantified emphysema in male heavy 327 
smokers: association with lung function decline. Thorax 2011;66:782–7. 328 
Page 18 of 49 AJRCCM Articles in Press. Published on 01-June-2015 as 10.1164/rccm.201501-0148OC 
 Copyright © 2015 by the American Thoracic Society 
16 
 
10. Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, Hasegawa M, Shimizu K, 329 
Betsuyaku T, Ito YM, Fuke S, Igarashi T, Akiyama Y, Ogura S. Annual change in 330 
pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am 331 
J Respir Crit Care Med 2012;185:44–52. 332 
11. Ingebrigtsen T, Thomsen SF, Vestbo J, van der Sluis S, Kyvik KO, Silverman EK, 333 
Svartengren M, Backer V. Genetic influences on Chronic Obstructive Pulmonary Disease 334 
- a twin study. Respir Med 2010;104:1890–5. 335 
12. Patel BD, Coxson HO, Pillai SG, Agustí AGN, Calverley PMA, Donner CF, Make BJ, 336 
Müller NL, Rennard SI, Vestbo J, Wouters EFM, Hiorns MP, Nakano Y, Camp PG, 337 
Nasute Fauerbach P V, Screaton NJ, Campbell EJ, Anderson WH, Paré PD, Levy RD, 338 
Lake SL, Silverman EK, Lomas DA. Airway wall thickening and emphysema show 339 
independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir 340 
Crit Care Med 2008;178:500–5. 341 
13. Zhou JJ, Cho MH, Castaldi PJ, Hersh CP, Silverman EK, Laird NM. Heritability of COPD 342 
and Related Phenotypes in Smokers. Am J Respir Crit Care Med 343 
2013;doi:10.1164/rccm.201302-0263OC. 344 
14. Urban Z, Gao J, Pope FM, Davis EC. Autosomal dominant cutis laxa with severe lung 345 
disease: synthesis and matrix deposition of mutant tropoelastin. 2005;124:1193–1199. 346 
15. Manichaikul A, Hoffman EA, Smolonska J, Gao W, Cho MH, Baumhauer H, Budoff M, 347 
Austin JHM, Washko GR, Carr JJ, Kaufman JD, Pottinger T, Powell CA, Wijmenga C, 348 
Zanen P, Groen HJM, Postma DS, Wanner A, Rouhani FN, Brantly ML, Powell R, Smith 349 
BM, Rabinowitz D, Raffel LJ, Hinckley Stukovsky KD, Crapo JD, Beaty TH, Hokanson 350 
JE, Silverman EK, et al. Genome-wide study of percent emphysema on computed 351 
tomography in the general population. The Multi-Ethnic Study of Atherosclerosis 352 
Lung/SNP Health Association Resource Study. Am J Respir Crit Care Med 353 
2014;189:408–18. 354 
16. Castaldi PJ, Cho MH, Estépar RSJ, McDonald M-LN, Laird N, Beaty TH, Washko G, 355 
Crapo JD, Silverman EK. Genome-Wide Association Identifies Regulatory Loci 356 
Associated with Distinct Local Histogram Emphysema Patterns. Am J Respir Crit Care 357 
Med 2014;doi:10.1164/rccm.201403-0569OC. 358 
17. Kong X, Cho MH, Anderson W, Coxson HO, Muller N, Washko G, Hoffman EA, Bakke 359 
P, Gulsvik A, Lomas DA, Silverman EK, Pillai SG. Genome-wide association study 360 
identifies BICD1 as a susceptibility gene for emphysema. Am J Respir Crit Care Med 361 
2011;183:43–9. 362 
18. Dijkstra AE, Postma DS, van Ginneken B, Wielpütz MO, Schmidt M, Becker N, 363 
Owsijewitsch M, Kauczor H-U, de Koning HJ, Lammers JW, Oudkerk M, Brandsma C-A, 364 
Bossé Y, Nickle DC, Sin DD, Hiemstra PS, Wijmenga C, Smolonska J, Zanen P, Vonk 365 
JM, van den Berge M, Boezen HM, Groen HJM. Novel Genes for Airway Wall Thickness 366 
Page 19 of 49  AJRCCM Articles in Press. Published on 01-June-2015 as 10.1164/rccm.201501-0148OC 
 Copyright © 2015 by the American Thoracic Society 
17 
 
Identified with Combined Genome Wide Association and Expression Analyses. Am J 367 
Respir Crit Care Med 2014;doi:10.1164/rccm.201405-0840OC. 368 
19. Cho MH, Castaldi P, Hersh CP, Barr RG, Tal-Singer R, Bakke P, Gulsvik A, Van Beek 369 
EJ, Coxson HO, Lynch DA, Washko GR, Laird N, Crapo J, Beaty T, Silverman EK. A 370 
Genome-Wide Association Study of Emphysema and Airway Quantitative Imaging 371 
Phenotypes. Am Thorac Soc Int Conf 2015. p. A2849. 372 
20. Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH, Curran-Everett D, 373 
Silverman EK, Crapo JD. Genetic epidemiology of COPD (COPDGene) study design. 374 
COPD, 2010/03/11 ed. 7:32–43. 375 
21. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, 376 
Lomas DA, MacNee W, Silverman EK, Tal-Singer R. Evaluation of COPD 377 
Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 378 
2008;31:869–73. 379 
22. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood 380 
DE. A randomized trial comparing lung-volume-reduction surgery with medical therapy 381 
for severe emphysema. N Engl J Med 2003;348:2059–73. 382 
23. Pillai SG, Ge D, Zhu G, Kong X, Shianna K V, Need AC, Feng S, Hersh CP, Bakke P, 383 
Gulsvik A, Ruppert A, Lodrup Carlsen KC, Roses A, Anderson W, Rennard SI, Lomas 384 
DA, Silverman EK, Goldstein DB. A genome-wide association study in chronic 385 
obstructive pulmonary disease (COPD): identification of two major susceptibility loci. 386 
PLoS Genet, 2009/03/21 ed. 2009;5:e1000421. 387 
24. Cho MH, Boutaoui N, Klanderman BJ, Sylvia JS, Ziniti JP, Hersh CP, DeMeo DL, 388 
Hunninghake GM, Litonjua AA, Sparrow D, Lange C, Won S, Murphy JR, Beaty TH, 389 
Regan EA, Make BJ, Hokanson JE, Crapo JD, Kong X, Anderson WH, Tal-Singer R, 390 
Lomas DA, Bakke P, Gulsvik A, Pillai SG, Silverman EK. Variants in FAM13A are 391 
associated with chronic obstructive pulmonary disease. Nat Genet, 2010/02/23 ed. 392 
2010;42:200–202. 393 
25. Cho MH, Castaldi PJ, Wan ES, Siedlinski M, Hersh CP, Demeo DL, Himes BE, Sylvia 394 
JS, Klanderman BJ, Ziniti JP, Lange C, Litonjua AA, Sparrow D, Regan EA, Make BJ, 395 
Hokanson JE, Murray T, Hetmanski JB, Pillai SG, Kong X, Anderson WH, Tal-Singer R, 396 
Lomas DA, Coxson HO, Edwards LD, MacNee W, Vestbo J, Yates JC, Agusti A, et al. A 397 
genome-wide association study of COPD identifies a susceptibility locus on chromosome 398 
19q13. Hum Mol Genet 2012;21:947–57. 399 
26. Cho MH, McDonald M-LN, Zhou X, Mattheisen M, Castaldi PJ, Hersh CP, Demeo DL, 400 
Sylvia JS, Ziniti J, Laird NM, Lange C, Litonjua AA, Sparrow D, Casaburi R, Barr RG, 401 
Regan EA, Make BJ, Hokanson JE, Lutz S, Dudenkov TM, Farzadegan H, Hetmanski JB, 402 
Tal-Singer R, Lomas DA, Bakke P, Gulsvik A, Crapo JD, Silverman EK, Beaty TH. Risk 403 
Page 20 of 49 AJRCCM Articles in Press. Published on 01-June-2015 as 10.1164/rccm.201501-0148OC 
 Copyright © 2015 by the American Thoracic Society 
18 
 
loci for chronic obstructive pulmonary disease: a genome-wide association study and 404 
meta-analysis. lancet Respir Med 2014;2:214–25. 405 
27. DeMeo DL, Hersh CP, Hoffman EA, Litonjua AA, Lazarus R, Sparrow D, Benditt JO, 406 
Criner G, Make B, Martinez FJ, Scanlon PD, Sciurba FC, Utz JP, Reilly JJ, Silverman 407 
EK. Genetic determinants of emphysema distribution in the national emphysema 408 
treatment trial. Am J Respir Crit Care Med 2007;176:42–48. 409 
28. Schroeder JD, McKenzie AS, Zach JA, Wilson CG, Curran-Everett D, Stinson DS, 410 
Newell JD, Lynch DA. Relationships between airflow obstruction and quantitative CT 411 
measurements of emphysema, air trapping, and airways in subjects with and without 412 
chronic obstructive pulmonary disease. AJR Am J Roentgenol 2013;201:W460–70. 413 
29. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate 414 
genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 415 
2012;44:955–9. 416 
30. Han B, Eskin E. Random-Effects Model Aimed at Discovering Associations in Meta-417 
Analysis of Genome-wide Association Studies. Am J Hum Genet 2011;88:586–98. 418 
31. De Bakker PIW, Ferreira M a R, Jia X, Neale BM, Raychaudhuri S, Voight BF. Practical 419 
aspects of imputation-driven meta-analysis of genome-wide association studies. Hum Mol 420 
Genet 2008;17:R122–8. 421 
32. Lin DY, Zeng D. Proper analysis of secondary phenotype data in case-control association 422 
studies. Genet Epidemiol 2009;33:256–65. 423 
33. Hao K, Bossé Y, Nickle DC, Paré PD, Postma DS, Laviolette M, Sandford A, Hackett TL, 424 
Daley D, Hogg JC, Elliott WM, Couture C, Lamontagne M, Brandsma C-A, van den 425 
Berge M, Koppelman G, Reicin AS, Nicholson DW, Malkov V, Derry JM, Suver C, Tsou 426 
JA, Kulkarni A, Zhang C, Vessey R, Opiteck GJ, Curtis SP, Timens W, Sin DD. Lung 427 
eQTLs to help reveal the molecular underpinnings of asthma. PLoS Genet 428 
2012;8:e1003029. 429 
34. Li MJ, Wang LY, Xia Z, Sham PC, Wang J. GWAS3D: Detecting human regulatory 430 
variants by integrative analysis of genome-wide associations, chromosome interactions 431 
and histone modifications. Nucleic Acids Res 2013;41:W150–8. 432 
35. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, 433 
and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids 434 
Res 2012;40:D930–4. 435 
36. Zhang K, Cui S, Chang S, Zhang L, Wang J. i-GSEA4GWAS: a web server for 436 
identification of pathways/gene sets associated with traits by applying an improved gene 437 
set enrichment analysis to genome-wide association study. Nucleic Acids Res, 2010/05/04 438 
ed. 2010;38:W90–5. 439 
Page 21 of 49  AJRCCM Articles in Press. Published on 01-June-2015 as 10.1164/rccm.201501-0148OC 
 Copyright © 2015 by the American Thoracic Society 
19 
 
37. Lee PH, O’Dushlaine C, Thomas B, Purcell SM. INRICH: interval-based enrichment 440 
analysis for genome-wide association studies. Bioinformatics 2012;28:1797–9. 441 
38. Wilk JB, Shrine NRG, Loehr LR, Zhao JH, Manichaikul A, Lopez LM, Smith AV, 442 
Heckbert SR, Smolonska J, Tang W, Loth DW, Curjuric I, Hui J, Cho MH, Latourelle JC, 443 
Henry AP, Aldrich M, Bakke P, Beaty TH, Bentley AR, Borecki IB, Brusselle GG, 444 
Burkart KM, Chen T, Couper D, Crapo JD, Davies G, Dupuis J, Franceschini N, et al. 445 
Genome-wide association studies identify CHRNA5/3 and HTR4 in the development of 446 
airflow obstruction. Am J Respir Crit Care Med 2012;186:622–32. 447 
39. Soler Artigas M, Loth DW, Wain L V, Gharib SA, Obeidat M, Tang W, Zhai G, Zhao JH, 448 
Smith AV, Huffman JE, Albrecht E, Jackson CM, Evans DM, Cadby G, Fornage M, 449 
Manichaikul A, Lopez LM, Johnson T, Aldrich MC, Aspelund T, Barroso I, Campbell H, 450 
Cassano PA, Couper DJ, Eiriksdottir G, Franceschini N, Garcia M, Gieger C, Gislason 451 
GK, et al. Genome-wide association and large-scale follow up identifies 16 new loci 452 
influencing lung function. Nat Genet 2011;43:1082–90. 453 
40. Hancock DB, Artigas MS, Gharib SA, Henry A, Manichaikul A, Ramasamy A, Loth DW, 454 
Imboden M, Koch B, McArdle WL, Smith A V, Smolonska J, Sood A, Tang W, Wilk JB, 455 
Zhai G, Zhao JH, Aschard H, Burkart KM, Curjuric I, Eijgelsheim M, Elliott P, Gu X, 456 
Harris TB, Janson C, Homuth G, Hysi PG, Liu JZ, Loehr LR, et al. Genome-wide joint 457 
meta-analysis of SNP and SNP-by-smoking interaction identifies novel loci for pulmonary 458 
function. PLoS Genet 2012;8:e1003098. 459 
41. Repapi E, Sayers I, Wain L V, Burton PR, Johnson T, Obeidat M, Zhao JH, Ramasamy A, 460 
Zhai G, Vitart V, Huffman JE, Igl W, Albrecht E, Deloukas P, Henderson J, Granell R, 461 
McArdle WL, Rudnicka AR, Barroso I, Loos RJ, Wareham NJ, Mustelin L, Rantanen T, 462 
Surakka I, Imboden M, Wichmann HE, Grkovic I, Jankovic S, Zgaga L, et al. Genome-463 
wide association study identifies five loci associated with lung function. Nat Genet, 464 
2009/12/17 ed. 2009;42:36–44. 465 
42. Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards 466 
LD, Lomas DA, Miller BE, Reynaert N, Tal-Singer R, Wouters EFM, Agustí A, Fabbri 467 
LM, Rames A, Visvanathan S, Rennard SI, Jones P, Parmar H, MacNee W, Wolff G, 468 
Silverman EK, Mayer RJ, Pillai SG. Systemic soluble receptor for advanced glycation 469 
endproducts is a biomarker of emphysema and associated with AGER genetic variants in 470 
patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 471 
2013;188:948–57. 472 
43. Molloy K, Hersh CP, Morris VB, Carroll TP, O’Connor CA, Lasky-Su JA, Greene CM, 473 
O’Neill SJ, Silverman EK, McElvaney NG. Clarification of the risk of chronic obstructive 474 
pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit 475 
Care Med 2014;189:419–27. 476 
44. Sørheim I-C, Bakke P, Gulsvik A, Pillai SG, Johannessen A, Gaarder PI, Campbell EJ, 477 
Agustí A, Calverley PMA, Donner CF, Make BJ, Rennard SI, Vestbo J, Wouters EFM, 478 
Page 22 of 49 AJRCCM Articles in Press. Published on 01-June-2015 as 10.1164/rccm.201501-0148OC 
 Copyright © 2015 by the American Thoracic Society 
20 
 
Paré PD, Levy RD, Coxson HO, Lomas DA, Hersh CP, Silverman EK. α₁-Antitrypsin 479 
protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large 480 
cohorts. Chest 2010;138:1125–32. 481 
45. Liao Y-C, Lo SH. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. 482 
Int J Biochem Cell Biol 2008;40:843–7. 483 
46. Zhou X, Thorgeirsson SS, Popescu NC. Restoration of DLC-1 gene expression induces 484 
apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular 485 
carcinoma cells. Oncogene 2004;23:1308–13. 486 
47. Healy KD, Hodgson L, Kim T-Y, Shutes A, Maddileti S, Juliano RL, Hahn KM, Harden 487 
TK, Bang Y-J, Der CJ. DLC-1 suppresses non-small cell lung cancer growth and invasion 488 
by RhoGAP-dependent and independent mechanisms. Mol Carcinog 2008;47:326–37. 489 
48. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, 490 
Kampf C, Wester K, Hober S, Wernerus H, Björling L, Ponten F. Towards a knowledge-491 
based Human Protein Atlas. Nat Biotechnol 2010;28:1248–50. 492 
49. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, Hasz R, Walters G, Garcia 493 
F, Young N, Foster B, Moser M, Karasik E, Gillard B, Ramsey K, Sullivan S, Bridge J, 494 
Magazine H, Syron J, Fleming J, Siminoff L, Traino H, Mosavel M, Barker L, Jewell S, 495 
Rohrer D, Maxim D, Filkins D, Harbach P, et al. The Genotype-Tissue Expression 496 
(GTEx) project. Nat Genet, 2013/05/30 ed. 2013;45:580–585. 497 
50. Campbell JD, McDonough JE, Zeskind JE, Hackett TL, Pechkovsky D V, Brandsma C-A, 498 
Suzuki M, Gosselink J V, Liu G, Alekseyev YO, Xiao J, Zhang X, Hayashi S, Cooper JD, 499 
Timens W, Postma DS, Knight DA, Lenburg ME, Hogg JC, Spira A. A gene expression 500 
signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. 501 
Genome Med 2012;4:67. 502 
51. Gelernter J, Kranzler HR, Sherva R, Almasy L, Herman AI, Koesterer R, Zhao H, Farrer 503 
LA. Genome-wide association study of nicotine dependence in American populations: 504 
identification of novel risk loci in both African-Americans and European-Americans. Biol 505 
Psychiatry 2015;77:493–503. 506 
52. Lazary J, Dome P, Csala I, Kovacs G, Faludi G, Kaunisto M, Dome B. Massive 507 
withdrawal symptoms and affective vulnerability are associated with variants of the 508 
CHRNA4 gene in a subgroup of smokers. In: Chen L, editor. PLoS One 2014;9:e87141. 509 
53. Han S, Yang B-Z, Kranzler HR, Oslin D, Anton R, Gelernter J. Association of CHRNA4 510 
polymorphisms with smoking behavior in two populations. Am J Med Genet B 511 
Neuropsychiatr Genet 2011;156B:421–9. 512 
54. Savale L, Chaouat A, Bastuji-Garin S, Marcos E, Boyer L, Maitre B, Sarni M, Housset B, 513 
Weitzenblum E, Matrat M, Le Corvoisier P, Rideau D, Boczkowski J, Dubois-Randé J-L, 514 
Page 23 of 49  AJRCCM Articles in Press. Published on 01-June-2015 as 10.1164/rccm.201501-0148OC 
 Copyright © 2015 by the American Thoracic Society 
21 
 
Chouaid C, Adnot S. Shortened telomeres in circulating leukocytes of patients with 515 
chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;179:566–71. 516 
55. Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence in patients with pulmonary 517 
emphysema. Am J Respir Crit Care Med 2006;174:886–93. 518 
56. Alder JK, Guo N, Kembou F, Parry EM, Anderson CJ, Gorgy AI, Walsh MF, Sussan T, 519 
Biswal S, Mitzner W, Tuder RM, Armanios M. Telomere Length is a Determinant of 520 
Emphysema Susceptibility. Am J Respir Crit Care Med 2011;doi:10.1164/rccm.201103-521 
0520OC. 522 
57. Nunes H, Monnet I, Kannengiesser C, Uzunhan Y, Valeyre D, Kambouchner M, 523 
Naccache J-M. Is telomeropathy the explanation for combined pulmonary fibrosis and 524 
emphysema syndrome?: report of a family with TERT mutation. Am J Respir Crit Care 525 
Med 2014;189:753–4. 526 
58. Barnes PJ. Emerging pharmacotherapies for COPD. Chest, 2008/12/09 ed. 527 
2008;134:1278–1286. 528 
59. Fang X, Li K, Tao X, Chen C, Wang X, Wang L, Wang DC, Zhang Y, Bai C, Wang X. 529 
Effects of phosphoinositide 3-kinase on protease-induced acute and chronic lung 530 
inflammation, remodeling, and emphysema in rats. Chest 2013;143:1025–35. 531 
60. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, 532 
Waltenberger J, Voelkel NF. Inhibition of VEGF receptors causes lung cell apoptosis and 533 
emphysema. 2000;106:1311–1319. 534 
61. Taraseviciene-Stewart L, Scerbavicius R, Choe K-H, Moore M, Sullivan A, Nicolls MR, 535 
Fontenot AP, Tuder RM, Voelkel NF. An animal model of autoimmune emphysema. Am J 536 
Respir Crit Care Med 2005;171:734–42. 537 
62. Giordano RJ, Lahdenranta J, Zhen L, Chukwueke U, Petrache I, Langley RR, Fidler IJ, 538 
Pasqualini R, Tuder RM, Arap W. Targeted induction of lung endothelial cell apoptosis 539 
causes emphysema-like changes in the mouse. J Biol Chem 2008;283:29447–60. 540 
63. Thomashow MA, Shimbo D, Parikh MA, Hoffman EA, Vogel-Claussen J, Hueper K, Fu 541 
J, Liu C-Y, Bluemke DA, Ventetuolo CE, Doyle MF, Barr RG. Endothelial microparticles 542 
in mild chronic obstructive pulmonary disease and emphysema. The Multi-Ethnic Study 543 
of Atherosclerosis Chronic Obstructive Pulmonary Disease study. Am J Respir Crit Care 544 
Med 2013;188:60–8. 545 
64. Stratelis G, Fransson SG, Schmekel B, Jakobsson P, Molstad S. High prevalence of 546 
emphysema and its association with BMI: A study of smokers with normal spirometry. 547 
2008/10/11 ed. 2008;1–7.doi:903492403 [pii] 10.1080/02813430802452732. 548 
Page 24 of 49 AJRCCM Articles in Press. Published on 01-June-2015 as 10.1164/rccm.201501-0148OC 
 Copyright © 2015 by the American Thoracic Society 
22 
 
65. Hoffman EA, Ahmed FS, Baumhauer H, Budoff M, Carr JJ, Kronmal R, Reddy S, Barr 549 
RG. Variation in the percent of emphysema-like lung in a healthy, nonsmoking 550 
multiethnic sample. The MESA lung study. Ann Am Thorac Soc 2014;11:898–907. 551 
66. Wan ES, Cho MH, Boutaoui N, Klanderman BJ, Sylvia JS, Ziniti JP, Won S, Lange C, 552 
Pillai SG, Anderson WH, Kong X, Lomas DA, Bakke PS, Gulsvik A, Regan EA, Murphy 553 
JR, Make BJ, Crapo JD, Wouters EF, Celli BR, Silverman EK, Demeo DL. Genome-Wide 554 
Association Analysis of Body Mass in Chronic Obstructive Pulmonary Disease. Am J 555 
Respir Cell Mol Biol 2010;doi:10.1165/rcmb.2010-0294OC. 556 
67. Diaz AA, Come CE, Ross JC, San José Estépar R, Han MK, Loring SH, Silverman EK, 557 
Washko GR. Association between airway caliber changes with lung inflation and 558 
emphysema assessed by volumetric CT scan in subjects with COPD. Chest 2012;141:736–559 
44. 560 
68. Smith BM, Hoffman EA, Rabinowitz D, Bleecker E, Christenson S, Couper D, Donohue 561 
KM, Han MK, Hansel NN, Kanner RE, Kleerup E, Rennard S, Barr RG. Comparison of 562 
spatially matched airways reveals thinner airway walls in COPD. The Multi-Ethnic Study 563 
of Atherosclerosis (MESA) COPD Study and the Subpopulations and Intermediate 564 
Outcomes in COPD Study (SPIROMICS). Thorax 2014;doi:10.1136/thoraxjnl-2014-565 
205160. 566 
69. Repapi E, Sayers I, Wain L V, Burton PR, Johnson T, Obeidat M, Zhao JH, Ramasamy A, 567 
Zhai G, Vitart V, Huffman JE, Igl W, Albrecht E, Deloukas P, Henderson J, Granell R, 568 
McArdle WL, Rudnicka AR, Barroso I, Loos RJF, Wareham NJ, Mustelin L, Rantanen T, 569 
Surakka I, Imboden M, Wichmann HE, Grkovic I, Jankovic S, Zgaga L, et al. Genome-570 
wide association study identifies five loci associated with lung function. Nat Genet 571 
2010;42:36–44. 572 
70. Wilk JB, Chen TH, Gottlieb DJ, Walter RE, Nagle MW, Brandler BJ, Myers RH, Borecki 573 
IB, Silverman EK, Weiss ST, O’Connor GT. A genome-wide association study of 574 
pulmonary function measures in the Framingham Heart Study. Am J Respir Crit Care 575 
Med, 2009/03/21 ed. 2009;5:e1000429. 576 
71. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciante KD, 577 
Franceschini N, van Durme YMTA, Chen T-HH, Barr RG, Schabath MB, Couper DJ, 578 
Brusselle GG, Psaty BM, van Duijn CM, Rotter JI, Uitterlinden AG, Hofman A, Punjabi 579 
NM, Rivadeneira F, Morrison AC, Enright PL, North KE, Heckbert SR, Lumley T, 580 
Stricker BHC, O’Connor GT, London SJ. Meta-analyses of genome-wide association 581 
studies identify multiple loci associated with pulmonary function. Nat Genet, 2009/12/17 582 
ed. 2009;42:45–52.  583 
584 
Page 25 of 49  AJRCCM Articles in Press. Published on 01-June-2015 as 10.1164/rccm.201501-0148OC 




Table 1: Baseline characteristics of subjects with quantitative imaging phenotypes.  Cases = GOLD Grade 2 or more severe (e.g. 











 Non-cases Cases Non-cases Cases Controls Cases Cases Controls Cases 
n 3062 3243 2132 901 145 1393 332 406 417 
Age 59.7 (8.6) 64.4 (8.3) 53 (6) 58.6 (8.1) 57.3 (9.4) 63.4 (7) 67.4 (5.9) 55.6 (9.4) 64.2 (9.3) 
Pack-years 39.7 (21.5) 
54.4 
(27.5) 






19.8 (14.1) 31 (18.2) 















Current smokers 1263 (41.2%) 
1199 
(37%) 
1838 (86.2%) 595 (66%) 58 (40%) 
480 
(34.5%) 
0 164 (40.4%) 
210 
(50.4%) 
FEV1, % predicted 91.3 (14.8) 57.4 (23) 92.2 (16.5) 59.5 (22) 
108.6 
(13.4) 
47.4 (15.5) 28.2 (7.3) 94.9 (9.2) 
52.5 
(16.9) 
%LAA-950 1.2 (0-26.9) 
7.5 (0-
61.9) 







0.5 (0-34.4) 7 (0-53.2) 
Perc15, HU -909.9 (22.8) 
-938.1 
(26.8) 










Pi10, mm 3.64 (0.11) 
3.69 
(0.14) 









Wall area percent 
(WAP) 
60.2 (2.8) 62.3 (3.1) 61.2 (3.3) 62.9 (3.3) 63.2 (3.7) 65.6 (4.1) 73.2 (3.8) 74.8 (2.9) 76.1 (3) 
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Table 2: Genome-wide significant associations.  %LAA-950: percent of low attenuation area less than -950 Hounsfield units; 
Perc15 - Hounsfield Units at the 15th percentile of the density histogram; WAP percentage of the wall area compared to the total 
bronchial area. 
 
Phenotype Chr Marker Name Closest Gene 
Effect Allele 
Allele Frequency Modified Random Effects Fixed Effects 
Nhw Aa P value Beta SE P value Beta Se 
Emphysema    
%LAA-950 4 rs13141641 HHIP T 0.59 0.89 1.7 x 10
-12
 0.12 0.023 8.4 x 10
-13
 0.12 0.018 
 15 rs55676755 CHRNA3 C 0.63 0.84 2.4 x 10
-9
 -0.11 0.017 1.4 x 10
-9
 -0.11 0.017 
 6 rs2070600 AGER T 0.04 0.01 4.6 x 10
-9
 -0.14 0.11 6.5 x 10
-8
 -0.24 0.044 
 8 rs75200691 DLC1 T 0.88 0.92 9.7 x 10
-9
 0.15 0.026 5.7 x 10
-9
 0.15 0.026 
 14 rs45505795 SERPINA10 C 0.04 0.008 1.4 x 10
-8
 -0.31 0.08 9.8 x 10
-9
 -0.31 0.053 
Perc 15 8 rs74834049 DLC1 A 0.12 0.08 6.0 x 10
-10
 -3.4 0.54 3.3 x 10
-10
 -3.4 0.54 
 4 rs13141641 HHIP T 0.59 0.89 8.4 x 10
-10
 -2.2 0.39 4.7 x 10
-10
 -2.2 0.36 
Airway             
WAP 4 rs142200419 MIR2054 T 0.98 N/A 4.6x10
-9
 0.24 1 8.8x10
-5
 0.9 0.23 
Gas trapping             
% 6 rs2070600 AGER T 0.04 0.01 3.5 x 10
-9
 -0.23 0.039 2.4 x 10
-9
 -0.23 0.039 
 21 rs55706246 LINC00310 A 0.11 0.03 1.3 x 10
-8
 0.28 0.18 2.1 x 10
-7
 0.15 0.029 
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Table 3: P-values for genetic variants previously reported in genome-wide association analyses(23–26, 39, 40, 69–71).  The risk 
allele for spirometric phenotypes denotes the allele associated with a lower FEV1 or FEV1/FVC ratio, and thus would be expected to 
increase risk for COPD.   The sign associated with the P-values denotes whether the direction of association is consistent with the 
direction for COPD (increase in %LAA-950, Pi10, wall area percent, or gas trapping; decrease in Perc15).  In Table 3b, results are 
grouped by whether the smaller directional P-value was found in emphysema phenotypes (top) or airway-related phenotypes (bottom).  
Genome-wide significant loci from Table 2 (e.g. HHIP) are not included here.  All refers to all subjects, case refers to all cases 
(GOLD 1-4 or 2-4). 
Table 3a: Variants from GWAS of moderate-to-severe or severe COPD 
SNP Chr Locus Risk Allele 
Emphysema Airway 
Gas Trapping 
%LAA-950 Perc15 Pi10 Wall Area Percent 
All Case All Case All Case All Case All Case 
rs626750 11 MMP12 G 2x10-5 4x10-7 6x10-6 7x10-7 -0.1 -0 0.2 -0.1 0.008 0.1 
rs4846480 1 TGFB2 A 2x10-6 3x10-5 1x10-4 5x10-4 -0.7 -0.4 0.2 -0.9 3x10-4 0.009 
rs7937 19 RAB4B T 2x10-6 0.03 6x10-5 0.03 0.9 -0.08 0.4 -0.04 9x10-4 0.2 
rs754388 14 RIN3 C 3x10-5 0.1 5x10-5 0.04 0.4 -0.5 0.04 -0.6 0.003 0.1 
rs7671167 4 FAM13A T 3x10-4 0.3 2x10-4 0.07 0.6 -0.8 0.1 -0.5 9x10-5 0.6 
 
Table 3b: Variants from GWAS of lung function 
SNP Chr Locus Risk Allele 
Emphysema Airway 
Gas Trapping 
%LAA-950 Perc15 Pi10 Wall Area Percent 
All Case All Case All Case All Case All Case 
rs153916 5 SPATA9-RHOBTB3 T 0.001 0.02 2x10-5 0.02 -0.2 -0.3 0.9 -0.7 0.002 0.1 
rs1529672 3 RARB C 8x10-4 0.06 2x10-4 0.08 0.5 -1 0.1 0.9 2x10-4 0.03 
rs2284746 1 MFAP2 G 0.002 0.2 0.002 0.1 -0.06 -0.5 0.9 1 8x10-4 0.07 
rs12899618 15 THSD4 A 0.003 0.2 0.02 0.3 0.7 0.4 0.02 0.3 0.003 0.6 
rs7765379 6 HLA-DQB1 T 0.004 0.05 0.04 0.08 -0.4 -0.5 -0.4 -0.2 0.2 0.9 
rs9978142 21 KCNE2-LINC00310 T 0.005 0.06 0.04 0.07 -0.01 -0.05 -0.5 -0.9 0.04 0.004 
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rs3817928 6 GPR126 A 0.01 0.5 0.01 0.8 -0.1 -0.3 0.4 0.4 0.006 0.2 
rs1036429 12 CCDC38 C 0.04 0.03 0.01 0.06 -0.5 -0.5 0.1 0.5 0.04 0.4 
rs11134779 5 ADAM19 G 0.02 0.1 0.01 0.2 0.5 0.3 0.5 -0.7 0.04 0.08 
rs11172113 12 LRP1 T 0.04 -0.9 0.2 -0.6 0.4 0.6 0.5 0.09 9x10-5 0.2 
rs993925 1 TGFB2-LYPLAL1 C 0.2 -0.3 0.1 -0.1 -0.8 -0.6 -1 -0.4 0.004 0.9 
rs7594321 2 DNER C 0.2 0.6 0.1 0.8 -0.4 0.3 -0.5 -1 0.07 0.2 
              
rs2798641 6 ARMC2 T 0.5 0.3 0.6 -0.4 0.1 0.03 8x10-4 0.004 0.06 -0.7 
rs10516526 4 GSTCD/INTS12/NPNT A 0.4 -0.3 0.4 -0.2 0.04 0.009 0.001 0.003 0.006 0.3 
rs11168048 5 HTR4 T 0.05 0.5 0.09 0.8 0.06 0.2 0.002 0.07 0.3 -0.5 
rs2865531 16 CFDP1 A -1 -0.7 -0.9 -0.8 0.08 0.4 0.007 0.07 0.3 -0.3 
rs2571445 2 TNS1 A 0.4 0.2 -0.3 0.4 1 -0.5 0.008 0.1 -0.2 -0.7 
rs11654749 17 KCNJ2 T -0.1 -0.05 -0.09 -0.04 0.4 -0.5 0.02 1 -0.5 -0.3 
rs1344555 3 MECOM T -0.8 -1 -0.5 -0.8 0.5 0.7 0.3 0.05 -0.1 0.9 
rs2857595 6 NCR3-AIF1 A 0.9 0.6 0.7 0.3 0.3 0.09 0.3 0.06 -0.6 0.6 
rs11001819 10 C10orf11 G -0.04 -0.01 -0.02 -0 0.7 0.8 0.07 0.1 -1 -0.1 
rs16909898 9 PTCH1 G -1 -0.1 0.7 -0.2 0.5 -0.8 0.2 -0.9 0.1 -0.9 
rs12447804 16 MMP15 T -0.2 -0.3 -0.3 -0.3 0.6 0.5 0.7 0.2 -0.6 -0.6 
rs7068966 10 CDC123 C -0.5 -0.5 0.8 -1 -0.1 -0.1 0.2 0.9 0.8 -0.7 
rs6903823 6 ZKSCAN3 G -0.7 0.9 1 0.8 0.7 0.9 0.9 -0.9 -0.4 -0.7 
rs12477314 2 HDAC4-FLJ43879 C -0.3 -0.08 -0.3 -0.1 -0.01 -0.05 -0.6 -0.5 -0.7 -0.1 
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Figure 1: Local association plots for genome-wide significant loci. a-e) %LAA-950, f) wall 
area percent, g) % gas trapping.  
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Supplemental Data 21 
Supplemental Methods 22 
Study Populations 23 
Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points 24 
(ECLIPSE; SCO104960, NCT00292552, www.eclipse-copd.com): ECLIPSE cases and controls 25 
were aged 40-75 with at least a 10 pack-year smoking history without other respiratory diseases 26 
and without known alpha-1 antitrypsin deficiency.  Cases were GOLD Grade 2 and above (post-27 
bronchodilator forced expiratory volume in 1 second (FEV1) < 80% predicted and FEV1/forced 28 
vital capacity (FVC) < 0.7); controls had no evidence of obstruction and FEV1 > 85% predicted.  29 
Details of the ECLIPSE study have been previously published(1). 30 
Genotyping was performed using the Illumina HumanHap 550 V3 (Illumina, San Diego, CA), 31 
and BeadStudio quality control, including reclustering on project samples was performed 32 
following Illumina guidelines. Quality control was performed using Python (www.python.org) 33 
and R (www.r-project.org) scripts in conjunction with plink (v1.05).  Subjects and markers with 34 
a call rate of < 95% were excluded.  Population stratification exclusion and adjustment on self-35 
reported white subjects was performed using EIGENSOFT Version 2.0.  Details of the 36 
genotyping and previous genome-wide association have been published(2).  Imputation was 37 
updated using MaCH and minimac with the 1000 Genomes Phase I v3 EUR reference panel as 38 
previously described(3), resulting in a total of 11,040,911 variants with Rsq > 0.3. 39 
Low-dose (120kVp and 40mAs) CT scans were performed at baseline, 1 year, and 3 year time 40 
points; baseline scans were used for the current analysis.  All scans were performed using 41 
multidetector CT scans (GE Healthcare, Milwaukee, Wis. or Siemens Healthcare, Erlangen, 42 
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Germany) and images were reconstructed using 1.0mm (Siemens) or 1.25mm (GE) contiguous 43 
slices and an intermediate spatial frequency reconstruction algorithm.  CT scanners were 44 
calibrated regularly using standard water calibration phantoms.  All CT scans were analyzed at 45 
the University of British Columbia using Pulmonary Workstation 2.0 software (VIDA 46 
Diagnostics, Coralville, IA, U.S.A.).  Airways were segmented using a region growing algorithm 47 
using the third (segmental) to fifth generation airways(4, 5).  Wall area percent was calculated 48 
using the mean value of measurements for selected segmental airways (the same as used for 49 
COPDGene below) across all lobes. 50 
National Emphysema Treatment Trial (NETT, www.nhlbi.nih.gov/health/prof/lung/nett/): 51 
NETT subjects had severe airflow obstruction by post-bronchodilator spirometry (FEV1 < 45% 52 
predicted) and evidence of emphysema on computed tomography (CT).  Subjects with 53 
significant sputum production or bronchiectasis were excluded.  Details of the NETT trial have 54 
been published(6). 55 
For the NETT Genetics Ancillary Study, we genotyped a subset of 382 self-reported white 56 
subjects without severe alpha-1 antitrypsin deficiency with available blood for genotyping who 57 
provided written consent. Genotyping was performed using the Illumina Quad 610 array 58 
(Illumina, San Diego, CA), with quality control, population stratification adjustment, and 59 
imputation procedures as previously described previously(2).  A separate set of principal 60 
components was calculated for the NETT cases.  Imputation was updated using MaCH and 61 
minimac with the 1000 Genomes Phase I v3 EUR reference panel(3) , resulting in a total of 62 
10,659,967 variants with Rsq > 0.3. 63 
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NETT CT scans were performed on one of three types of scanners (General Electric, Fairfield, 64 
CT; Siemens, Malvern, PA; or Picker International, Toronto, ON, Canada) with a range of 2- to 65 
8-mm slice thickness, with 75% of the scan data from 4 to 5 mm. Densitometric measures were 66 
performed with the Pulmonary Analysis Software Suite (PASS, Iowa City, IA).  Airway 67 
measurements were obtained using 3D Slicer (www.Slicer.org) and Airway Inspector 68 
(www.airwayinspector.org) at Brigham and Women’s Hospital. The full width at half-maximum 69 
(FWHM) method was used to measure the wall thickness and wall area of each airway.  70 
Norway (GenKOLS, Genetics of Chronic Obstructive Lung Disease, GSK code RES11080): 71 
GenKOLS cases and controls had at least a > 2.5 pack year smoking history.  Cases had post-72 
bronchodilator FEV1 < 80% predicted and FEV1/FVC < 0.7, while controls had normal 73 
spirometry.   Subjects with severe alpha-1 antitrypsin deficiency and other lung diseases (aside 74 
from asthma) were excluded.  Details of the GenKOLS study have been previously published(7). 75 
Genotyping was performed using Illumina HumanHap 550 arrays (Illumina, San Diego, CA), 76 
with quality control, population stratification adjustment, and imputation procedures as described 77 
previously.  A separate set of principal components was calculated for the subset of subjects with 78 
CT imaging data.  Imputation was updated using MaCH and minimac with the 1000 Genomes 79 
Phase I v3 EUR reference panel(3), resulting in a total of 10,657,975 variants with Rsq > 0.3. 80 
High-resolution CT chest scans were performed on a subset of the cohort using a GE LightSpeed 81 
Ultra.  A low spatial frequency reconstruction algorithm was used for density measurements, and 82 
a high spatial frequency algorithm (bone) for airway measurements. Images were analyzed at the 83 
James Hogg iCAPTURE Centre (Vancouver, BC, Canada).  Emphysema extent was assessed on 84 
lung images segmented using a modified boarder tracing algorithm with prior position 85 
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knowledge, and the extent of emphysema was assessed using the percentage of lung voxels with 86 
attenuation values less than -950 Hounsfield units (HU).  Airways with an internal perimeter > 87 
6mm were identified on the CT scans and measured using the Full Width at Half Maximum 88 
algorithm.  Details on the imaging techniques in GenKOLS have been previously described(8). 89 
COPDGene (NCT00608764, www.copdgene.org).  COPDGene subjects were of non-Hispanic 90 
white or African-American ancestry, aged 45-80 years old, with a minimum of 10 pack-years of 91 
smoking, and without a history of lung disease other than asthma.  Subjects found to have 92 
evidence of other lung disease on CT, such as significant bronchiectasis or interstitial lung 93 
disease, were excluded from the current analysis.  Genotyping was performed by Illumina (San 94 
Diego, CA) on the HumanOmniExpress array, with quality control and imputation as previously 95 
described(3), resulting in a total of 11,437,352 variants for non-Hispanic whites and 22,904,273 96 
for African-Americans with Rsq > 0.3. 97 
CT chest imaging was performed on all subjects using a standardized protocol(9).  Quantitative 98 
analysis utilized the lower-spatial-resolution smooth reconstruction algorithm.  Analysis of 99 
emphysema severity was performed on segmented lung images by using the Slicer software 100 
package (http://www.slicer.org/).  Emphysema percentage was defined as all lung voxels with a 101 
CT attenuation value of less than −950 HU. Airway analysis was performed by using the VIDA 102 
Pulmonary Workstation, version 2.0 (Vida Diagnostics, Coralville, Iowa, 103 
http://www.vidadiagnostics.com/).  Measurements were obtained along the center line of the 104 
lumen, in the middle third of the airway segment, for one segmental airway of each lung lobe 105 
including the lingula; the mean value across all lobes was used for analysis. Details of the 106 
imaging techniques have been described previously(10). 107 
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Additional Genetic Analysis Methods 108 
Imputed genotypes were included for analysis if they had an Rsq of 0.3 or greater.    Individual 109 
genetic variants were included in the meta-analysis if they were missing in no more than one 110 
study (except for gas trapping, where the variant was required to be present in both COPDGene 111 
populations); variants with minor allele frequency < 1% overall or < 0.5% in individual studies 112 
were excluded, resulting in 6.9 (gas trapping) to 7.6 million (all other phenotypes) total analyzed 113 
variants.  All variants were oriented to the ‘+’ strand of the hg19 reference assembly.  P-values 114 
were not adjusted for multiple comparisons. 115 
Our primary analyses were performed in all subjects, with a method used to specifically address 116 
ascertainment.  We additionally assessed the impact of each of the top variants in cases and non-117 
cases separately using the same methods as for the overall meta-analysis.  For results in the 118 
SERPINA10 locus, we performed a meta-analysis conditioning on the SERPINA1 Z allele by 119 
performing a linear regression including this SNP as a covariate in the model, and performing a 120 
meta-analysis on the target SNP.  121 
 122 
To determine whether loci previously described in association with lung function were enriched 123 
for nominally significant (P < 0.05) associations in our quantitative imaging, we performed a 124 
Fisher’s exact test.  To determine whether any of the variants that we identified in this analysis 125 
were expression quantitative trait loci in lung, we searched the published dataset of Hao et al 126 
(11) and data from the GTeX consortium.    Since Hao et al report only significant genotyped 127 
loci, we searched for variants in linkage disequilibrium with our top-reported variants using 128 
plink.  VEGAS version 0.8.27 (12) gene-based analysis was performed using the CEU reference 129 
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haplotypes and including the top 20 percent of SNPs for a given gene. For the GRAIL 130 
(http://www.broadinstitute.org/mpg/grail/grail.php)(13) analysis, HapMap2 CEU variants  were 131 
pruned for linkage disequilibrium using plink(14) with 250kb windows and an r
2
 of 0.1. Results 132 
with overall P-value < 1x10
-4
 were input as seed and query regions, including text from PubMed 133 
articles up to May 2012.  For the analysis using iGSEA4GWAS(15), default settings of 500kb up 134 
and downstream boundaries and canonical pathways was used.  For DEPICT(16) 135 
(http://www.broadinstitute.org/mpg/depict/), SNPs were pruned to 500kb boundaries with an r2 136 
of 0.05.  For INRICH(17), input files were pruned using an r2 of 0.05 using a range of 20kb up 137 
and downstream with 10,000 replicates.  MAGENTA(18) was run using version July 2011, 138 
under default settings.  Overlap between results from these analyses was examined using an FDR 139 
< 0.05 for iGSEA4GWAS, P < 0.005 for DEPICT, P < 0.05 for INRICH, and nominal GSEA 140 
75
th
 percentile P  < 0.05, to allow similar number of results in each dataset. 141 
For the analysis of enhancer and promoter enrichment in ENCODE data, we used Haploreg 142 
v2(19), using SNPs with GWAS P-values of < 1x10
-6
 for the top GWAS results, an r
2
 of 0.8 and 143 
using 1000 Genomes EUR Pilot data as background for enrichment.  Briefly, Haploreg calculates 144 
enrichment using the background set of variants to determine the level of overlap of specifically 145 
annotated regions from the ENCODE project, and calculates an uncorrected binomial P-value.    146 
Linkage disequilibrium between SNPs was estimated using the 1000 Genomes reference data in 147 
SNAP(20), the 1000 Genomes EUR reference data, or (for the calculation with the reported 148 
DLC1 variant) the imputed genotypes in the African-American COPDGene samples, and 149 
calculated using plink. All chromosomal positions are given using the NCBI37/hg19 assembly, 150 
and alleles are referenced to the + strand. 151 
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Supplemental Results 152 
Genome-wide Association Quality Control 153 
None of the individual genome-wide association results for each cohort and phenotype 154 
demonstrated evidence of substantial inflation of p-values (λGC range 1.0 – 1.02).  For the meta-155 
analyses, the fixed effects analysis for Pi10 in all subjects demonstrated minimal evidence of 156 
inflation (λGC =1.06, λGC1000 =1.01), the remainder of both fixed and modified random effects 157 
studies did not show evidence of inflation (λGC = 1.02).   158 
 159 
Supplemental Tables 160 
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Table S1: Detailed results for the top genome-wide association results.  Results given for each cohort.  For the analyses involving 
all subjects, the second line shows the P-values from the SPREG(21) analysis (for COPDGene and Norway) or for cases only 
(ECLIPSE). 
Phenotype Cohort Closest Gene Marker Name COPDGene non-Hispanic Whites COPDGene African-Americans ECLIPSE NETT Norway 
    Beta SE P-value Beta SE P-value Beta SE P-value Beta SE P-value Beta SE P-value 
%LAA-950 All HHIP rs13141641 0.16 0.024 7.6x10-11 0.11 0.056 0.059 0.11 0.038 0.0031 0.004 0.067 0.95 0.12 0.076 0.12 






     
0.15 
  CHRNA3 rs55676755 -0.13 0.025 9.4x10-8 -0.094 0.045 0.037 -0.092 0.039 0.018 -0.02 0.066 0.76 -0.097 0.077 0.21 






     
0.47 
  AGER rs2070600 -0.35 0.058 1.6x10-9 -0.22 0.18 0.21 -0.22 0.1 0.029 0.26 0.14 0.065 -0.1 0.18 0.56 
  






     
0.41 
  DLC1 rs75200691 0.16 0.037 2.6x10-5 0.18 0.063 0.0042 0.13 0.057 0.027 0.11 0.097 0.25 0.17 0.11 0.11 
  






     
0.1 
  SERPINA10 rs45505795 -0.28 0.074 1.7x10-4 -0.56 0.23 0.013 -0.39 0.1 0.00011 -0.064 0.16 0.7 -0.64 0.21 0.0024 
  






     
0.0069 
Perc15, HU All DLC1 rs74834049 -3.3 0.7 3.0x10-6 -3.6 1.4 0.011 -3 1.5 0.052 -3.5 2.1 0.095 -5.3 2.3 0.02 






     
0.017 
  
HHIP rs13141641 -2.5 0.45 1.7x10-8 -1 1.2 0.42 -3 0.99 0.0022 -0.25 1.4 0.86 -1.8 1.5 0.23 






     
0.3 
WAP, % All 
MIR2054 rs142200419 1.3 0.27 1.1x10-6    1.8 0.67 0.0093 0.56 1.4 0.7 -2.8 0.71 6.9x10-5 
  
    8.0x10-6      0.0016      7.7x10-5 
Gas trapping, % All AGER rs2070600 -0.24 0.042 1.4x10-8 -0.13 0.15 0.39 
         




         
  
LINC00310 rs55706246 0.11 0.03 2.3x10-4 0.45 0.099 4.7x10-6 
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Table S2: Additional results from each genome-wide study.  Results with P < 1x10-6 in either the modified random effects or fixed 
effects analysis are shown. 
Phenotype Group Chr Marker Name Closest Gene Effect 
Allele 
Allele Frequency Modified Random Effrects Fixed Effects 
Emphysema      Nhw Aa P value Beta SE P value Nhw Aa 
%LAA-950, % All 9 rs3919995 ZNF462 A 0.59 0.5 1.3x10-7 -0.081 0.023 8.1x10-8 -0.088 0.016 
  20 rs183345681 CHRNA4 A 0.23 0.18 1.8x10-7 -0.12 0.023 1.1x10-7 -0.12 0.023 
  14 rs117167774 LOC100506433 T 0.013 0.013 1.8x10-7 0.47 0.23 0.00013 0.33 0.086 
  2 rs360488 FAM84A A 0.23 0.082 3.7x10-7 0.09 0.038 3.0x10-7 0.11 0.021 
  1 rs7512679 TGFB2 T 0.24 0.47 4.5x10-7 0.092 0.018 2.9x10-7 0.092 0.018 
  8 rs7823498 NRG1 T 0.79 0.73 4.6x10-7 -0.098 0.019 3.1x10-7 -0.098 0.019 
  11 rs7947523 MIR4300 C 0.68 0.44 4.9x10-7 -0.086 0.048 0.00014 -0.064 0.017 
  20 rs2070755 PCK1 C 0.49 0.4 5.3x10-7 0.11 0.047 0.00041 0.058 0.016 
  8 rs10109725 CSMD1 T 0.03 0.0069 6.3x10-7 0.28 0.14 8.6x10-6 0.25 0.055 
  5 rs924633 DNAH5 A 0.95 0.92 9.2x10-7 0.18 0.092 8.1x10-5 0.14 0.036 
  4 rs62343714 LOC401164 T 0.092 0.16 1.2x10-6 0.12 0.036 8.8x10-7 0.13 0.026 
  19 rs7937 MIA-RAB4B T 0.57 0.3 1.5x10-6 -0.08 0.016 9.7x10-7 -0.08 0.016 
 Cases 11 rs608194 MMP12 T 0.18 0.33 1.4x10-7 0.05 0.074 2.9x10-5 0.11 0.027 
  6 rs72971709 GRIK2 A 0.013 0.0029 2.6x10-7 0.38 0.31 2.6x10-5 0.44 0.1 
  18 rs12605822 ANKRD12 A 0.13 0.11 3.6x10-7 0.17 0.072 3.0x10-6 0.15 0.031 
  14 rs3811345 LINC00617 A 0.87 0.86 4.4x10-7 0.16 0.03 2.8x10-7 0.16 0.03 
  15 rs9788721 AGPHD1 T 0.62 0.62 5.5x10-7 -0.1 0.025 3.5x10-7 -0.11 0.021 
  1 rs72482608 PRRX1 A 0.62 0.52 7.6x10-7 -0.11 0.021 4.8x10-7 -0.11 0.021 
  5 rs13184316 ARL15 A 0.23 0.05 8.2x10-7 0.07 0.1 0.78 -0.0073 0.027 
Perc15, HU All 1 rs72637224 XCL2 T 0.05 0.14 3.3x10-7 3.6 1.2 2.1x10-7 3.5 0.68 
  16 rs9933712 ERCC4 A 0.021 0.38 4.2x10-7 5.2 1.8 2.6x10-7 3.7 0.72 
  20 rs183345681 CHRNA4 A 0.23 0.18 4.7x10-7 2.4 0.47 3.0x10-7 2.4 0.47 
  12 rs75751297 FLJ31485 A 0.47 0.36 6.6x10-7 2.4 0.48 4.2x10-7 2.4 0.48 
  11 rs7125940 MIR4300 T 0.34 0.58 6.9x10-7 -1.9 1 8.3x10-5 -1.4 0.35 
  15 rs144442299 UNC13C T 0.018 0.0051 7.8x10-7 -5.4 2.9 5.4x10-7 -7.4 1.5 
  20 rs2070755 PCK1 C 0.49 0.4 8.5x10-7 -2.5 1.1 0.0092 -0.88 0.34 
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  3 rs111646341 LSAMP A 0.97 0.98 9.0x10-7 5.8 1.8 5.7x10-7 5.6 1.1 
  14 rs45505795 SERPINA10 C 0.038 0.0076 9.5x10-7 6.4 2.7 2.6x10-6 5.2 1.1 
  4 rs10016562 TRPC3 T 0.62 0.73 1.0x10-6 1.6 0.5 6.4x10-7 1.7 0.35 
  8 rs7823498 NRG1 T 0.79 0.73 1.0x10-6 2 0.4 6.4x10-7 2 0.4 
  15 rs9788721 AGPHD1 T 0.62 0.62 1.1x10-6 1.7 0.35 6.7x10-7 1.7 0.35 
  6 rs2647050 HLA-DQB1 T 0.65 0.65 1.2x10-6 1.6 0.48 7.7x10-7 1.7 0.35 
  20 rs6080212 KIF16B A 0.16 0.15 1.4x10-6 -2.2 0.45 8.8x10-7 -2.2 0.45 
 Cases 10 rs139326003 MBL2 A 0.12 0.089 1.6x10-7 4.2 0.95 1.2x10-7 3.9 0.74 
  11 rs185888204 OR8B3 A 0.11 0.11 1.9x10-7 -7.1 3 2.5x10-6 -6.1 1.3 
  15 rs503464 CHRNA5 A 0.22 0.27 2.5x10-7 -3.2 0.6 1.5x10-7 -3.2 0.6 
  18 rs12605822 ANKRD12 A 0.13 0.11 4.0x10-7 -3.3 1.4 5.3x10-7 -3.6 0.71 
  1 rs72482608 PRRX1 A 0.62 0.52 5.0x10-7 2.5 0.48 3.2x10-7 2.5 0.48 
  11 rs654600 MMP12 A 0.83 0.72 5.2x10-7 -1.7 1.6 5.1x10-5 -2.5 0.63 
  4 rs13140744 TRPC3 T 0.38 0.26 8.9x10-7 -2.2 0.64 5.7x10-7 -2.4 0.48 
  1 rs75565482 XCL2 A 0.95 0.91 1.1x10-6 5.1 1.6 7.1x10-7 5.2 1.1 
  14 rs3811345 LINC00617 A 0.87 0.86 1.5x10-6 -3.4 0.7 9.5x10-7 -3.4 0.7 
Airway              
Pi10 All 8 rs13281609 CSMD3 T 0.047 0.0079 3.2x10-7 -0.044 0.01 2.2x10-7 -0.043 0.0082 
  11 rs113835537 CTSF A 0.84 0.83 8.5x10-7 0.012 0.0023 5.4x10-7 0.012 0.0023 
  1 rs654950 HIVEP3 C 0.42 0.12 8.6x10-7 -0.011 0.0055 3.5x10-6 -0.0089 0.0019 
 Cases 3 rs168302 GRM7 T 0.66 0.87 9.8x10-8 -0.016 0.004 6.0x10-8 -0.017 0.0032 
  9 rs4877691 FAM75D1 A 0.24 0.38 6.6x10-7 -0.017 0.0078 2.0x10-6 -0.016 0.0034 
  2 rs115089939 LOC647012 T 0.99 1 1.1x10-6 -0.086 0.017 7.2x10-7 -0.086 0.017 
  5 rs79581221 ATG10 T 0.014 0.0017 1.1x10-6 -0.077 0.016 7.4x10-7 -0.077 0.016 
WAP All 1 rs12724666 PDZK1P1 A 0.033 0.0092 8.7x10-8 1.1 0.2 5.9x10-8 1.1 0.2 
  8 rs2513900 AZIN1 C 0.51 0.74 2.6x10-7 0.23 0.043 1.7x10-7 0.23 0.043 
  17 rs3826538 RPA1 T 0.072 0.27 1.5x10-6 -0.35 0.071 9.3x10-7 -0.35 0.071 
 Cases 3 rs76493322 GRM7 A 0.46 0.45 3.1x10-7 -0.36 0.069 2.0x10-7 -0.36 0.069 
  2 rs10932600 ATIC A 0.62 0.73 1.3x10-6 -0.32 0.065 8.4x10-7 -0.32 0.065 
  1 rs61797053 KIAA1324 A 0.067 0.019 1.5x10-6 0.67 0.14 9.5x10-7 0.67 0.14 
Gas Trapping              
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 All 4 rs1512281 HHIP-AS1 A 0.59 0.88 2.3x10-7 0.082 0.016 1.9x10-7 0.082 0.016 
  8 rs74834049 DLC1 A 0.11 0.082 6.1x10-7 0.12 0.024 5.0x10-7 0.12 0.024 
  1 rs6669119 PAX7 T 0.1 0.12 9.90E-07 -0.14 0.062 1.60E-06 -0.11 0.024 
  8 rs2844036 ANKRD46 A 0.78 0.88 1.10E-06 -0.11 0.022 8.60E-07 -0.11 0.022 
  10 rs655766 BAMBI T 0.28 0.22 1.20E-06 0.08 0.016 9.90E-07 0.08 0.016 
 Cases 12 rs10875912 MLL2 T 0.66 0.67 8.30E-08 -0.091 0.017 7.10E-08 -0.091 0.017 
  20 rs430086 MACROD2 A 0.98 0.86 2.50E-07 0.16 0.16 9.80E-06 0.19 0.044 
  2 rs72822868 SNAR-H T 0.91 0.98 5.20E-07 0.23 0.046 4.30E-07 0.23 0.046 
  12 rs2460882 SP1 T 0.84 0.38 6.40E-07 0.11 0.022 5.30E-07 0.11 0.022 
  11 rs1789001 OR9G4 A 0.57 0.43 6.80E-07 0.079 0.024 5.60E-07 0.084 0.017 
  6 rs12527942 MRPL14 T 0.03 0.048 9.40E-07 0.32 0.34 0.033 0.1 0.047 
  8 rs13259853 CSMD1 A 0.44 0.099 1.00E-06 -0.088 0.022 8.30E-07 -0.09 0.018 
  17 rs12449664 NTN1 A 0.14 0.084 1.10E-06 0.15 0.03 9.10E-07 0.15 0.03 
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Table S3: Lookup of top quantitative CT association results in all subjects within separate analyses in COPD cases and non-cases. 
Phenotype Chr Marker Name Closest Gene Effect Allele 
Cases Non-cases 
Modified Random Effects Fixed Effects Modified Random Effects Fixed Effects 
P value Beta SE P value Beta Se P value Beta SE P value Beta Se 
%LAA-950 4 rs13141641 HHIP T 4.4 x 10
-5
 0.09 0.030 3.6 x 10
-5
 0.09 0.021 2.0x10
-2
 0.05 0.021 1.5 x 10
-2
 0.05 0.021 
 15 rs55676755 CHRNA3 C 3.2 x 10
-6
 -0.08 0.034 3.1 x 10
-6
 -0.09 0.021 5.1 x 10
-1
 0.02 0.022 4.4 x 10
-1
 0.02 0.022 
 6 rs2070600 AGER T 1.9 x 10
-2
 -0.08 0.095 3.1 x 10
-2
 -0.12 0.054 1.9 x 10
-3
 -0.11 0.126 4.4 x 10
-3
 -0.18 0.073 
 8 rs75200691 DLC1 T 6.3 x 10
-3
 0.09 0.032 4.4 x 10
-3
 0.09 0.032 1.4 x 10
-4
 0.12 0.032 9.4 x 10
-5
 0.12 0.032 
 14 rs45505795 SERPINA10 C 3.9 x 10
-4
 -0.21 0.056 2.6 x 10
-4
 -0.21 0.056 1.8 x 10
-2
 -0.18 0.073 1.4 x 10
-2
 -0.18 0.073 
Perc 15 8 rs74834049 DLC1 A 7.5 x 10
-4
 -2.6 0.74 5.1 x 10
-4
 -2.6 0.74 2.7 x 10
-4
 -0.27 0.81 1.9 x 10
-4
 -2.4 0.064 
 4 rs13141641 HHIP T 8.3 x 10
-5
 -2.0 0.49 5.5 x 10
-5
 -2.0 0.49 2.7 x 10
-1
 -0.53 0.43 2.2 x 10
-1
 -0.52 0.43 
Airway                 
WAP 4 rs142200419 MIR2054 T 3.1x10
-4
 0.30 1 3.9x10
-2
 0.7 0.34 3.7x10
-3
 -0.29 1.23 1.7x10
-2
 0.71 0.30 
Gas trapping                 
% 6 rs2070600 AGER T 5.2 x 10
-3
 -0.15 0.083 4.4 x 10
-3
 -0.13 0.047 5.1 x 10
-4
 -0.18 0.05 4.3 x 10
-4
 -0.18 0.050 
 21 rs55706246 LINC00310 A 3.7 x 10
-3
 0.15 0.099 3.2 x 10
-3
 0.09 0.032 2.2 x 10
-2
 0.19 0.159 3.9 x 10
-2
 0.08 0.038 
 
 
Table S4: Top overall quantitative CT loci not previously reported in case-control association analyses for moderate-to-severe and 




Closest Gene Effect Allele 
Moderate-To-Severe COPD Severe COPD 
P-value Beta P-value Beta 





8 rs75200691 DLC1 T 0.35 0.05 0.21 0.08 
8 rs74834049 DLC1 A 0.39 -0.04 0.20 -0.08 





4 rs142200419 MIR2054 T 0.25 0.19 0.47 0.14 
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